Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic Accuracy of the Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection Among Cirrhotic Patients: the SEPT9_CROSS Study

NCT03311152 is registered in ClinicalTrials.gov with Central Hospital, Nancy, France as lead sponsor.

NCT NCT03311152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03311152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic Accuracy of the Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection Among Cirrhotic Patients: the SEPT9_CROSS Study
Lead sponsor
Central Hospital, Nancy, France
Phase
Not applicable
Overall status
Completed
Start date
February 12, 2018
Completion date
October 17, 2024
Enrollment
639 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, hepatocellular carcinoma